Skip to main
GOVX
GOVX logo

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc is recognized for its potential upside attributed to its current distressed valuation level, emphasizing an attractive investment opportunity. The company’s key clinical program, GEO-CM04S1, has demonstrated a strong safety profile and durable immunogenicity, positioning it favorably within the competitive landscape of next-generation COVID-19 vaccines. Additionally, ongoing efforts to enhance liquidity and strategic considerations related to mergers and acquisitions suggest proactive management aimed at strengthening the company's market position.

Bears say

Geovax Labs Inc faces significant challenges due to the recent halting of an mRNA comparator arm in a chronic lymphocytic leukemia (CLL) study, which raises concerns about the overall efficacy of its vaccine candidates. Despite the GEO-CM04S1 arm meeting interim immune-response targets, the failure of the comparator may negatively impact the company's credibility and future funding opportunities. Furthermore, the reliance on completing ongoing studies without a robust track record can lead to increased investor skepticism regarding the viability and marketability of its pipeline products.

Geovax Labs (GOVX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.